REGENXBIO Inc. has announced positive interim data from its Phase I/II AFFINITY DUCHENNE trial involving RGX-202, a potential gene therapy for Duchenne muscular dystrophy. The trial results indicate consistent functional, safety, and biomarker benefits, with participants in dose level 2 surpassing external natural history controls on key functional measures. Biomarker data showed robust microdystrophin expression, with one participant achieving 118.6% expression compared to controls. The trial, which aims to enroll around 30 patients in the U.S. and Canada by 2025, supports a potential Biologics License Application submission using the accelerated approval pathway in mid-2026. REGENXBIO plans to release top-line data in the first half of 2026. A webcast discussing these developments is scheduled for 8:00 a.m. EST, accessible via the company's website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.